Argenx

Neuromuscular Disorders

Research activity centres on generalized myasthenia gravis, ocular myasthenia gravis, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, amyotrophic lateral sclerosis, and congenital myasthenic syndromes, with additional interest in pediatric and adult forms of these conditions.

  • Myasthenia gravis
  • Chronic inflammatory demyelinating polyneuropathy
  • Amyotrophic lateral sclerosis

Trials also extend to AChR-antibody positive and seronegative disease subtypes, reflecting broad involvement across autoimmune neuromuscular weakness.

Autoimmune Thrombocytopenia

The sponsor funds studies in primary immune thrombocytopenia and chronic immune thrombocytopenia, including work that spans adult and adolescent populations.

  • Primary immune thrombocytopenia
  • Chronic immune thrombocytopenia
  • Immune-mediated platelet disorders

These programs focus on autoimmune platelet destruction and persistent bleeding risk associated with reduced platelet counts.

Connective Tissue and Systemic Autoimmune Disease

Clinical research includes primary Sjögren’s syndrome, systemic sclerosis, idiopathic inflammatory myopathy, dermatomyositis, and related myositis syndromes.

  • Primary Sjögren’s syndrome
  • Systemic sclerosis
  • Dermatomyositis

Additional activity covers active idiopathic inflammatory myopathy and broader systemic autoimmune manifestations affecting muscle, skin, and exocrine glands.

Studies address bullous pemphigoid and thyroid eye disease, with attention to immune-mediated skin blistering and orbital inflammation.

  • Bullous pemphigoid
  • Thyroid eye disease
  • Autoimmune skin disorders

These areas reflect interest in disorders driven by pathogenic autoantibodies and inflammatory tissue injury.

Transplantation and Renal Complications

Argenx also supports research in kidney transplantation, including antibody-mediated rejection and delayed graft function, alongside studies examining renal impairment and transplant-related immune complications.

  • Antibody-mediated rejection
  • Delayed graft function
  • Renal impairment

These programs extend the sponsor’s clinical scope into post-transplant immune control and kidney graft outcomes.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria France Germany Italy Latvia +4
  • Study of Efgartigimod for Adults with Thyroid Eye Disease

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Estonia Germany Greece +4
  • Study on the Safety and Efficacy of ARGX-119 for Adults with Amyotrophic Lateral Sclerosis (ALS)

    Not recruiting

    2 1
    Investigated diseases:
    Belgium Denmark France The Netherlands Sweden
  • Study on Efgartigimod IV for Adults with Seronegative Generalized Myasthenia Gravis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Cyprus Czechia Denmark Finland France +9
  • Study on the Safety and Efficacy of Empasiprubart for Adults with Dermatomyositis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Greece Italy Poland Spain
  • Study on Efgartigimod Alfa and Prednisone for Adults with Bullous Pemphigoid

    Not recruiting

    4 1 1
    Bulgaria Croatia Czechia France Germany Greece +8